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Skin irritationa b s t r a c t
Bacterial cellulose (BC) is a highly pure form of cellulose, produced in the form of a swollen membrane by
several bacteria that demonstrated to be able to modulate the skin release of model drugs. In the present
study, the skin irritation potential of BC was evaluated in human subjects. BC membranes with and
without glycerin (acting as plasticizer) were tested. No significant differences were observed for transepi-
dermal water loss (TEWL) measurements in comparison with negative control, 2 and 24 h after patch
removal, which is an indicator of an absence of barrier disruption. Similar results were found for ery-
thema. Clinical scores were zero at both times for all volunteers, with the exception of five volunteers
that exhibited weak reactions. BC with glycerin provided a skin moisturizing effect statistically higher
than the negative control (p = 0.044), which was not observed for BC alone. The good skin tolerance found
after a single application under occlusion reinforces the putative interest of BC membranes as supports
for drug topical delivery. Besides modifying the mechanical properties, the inclusion of glycerin results
in a skin moisturizing effect which could be clinically relevant for the treatment for skin diseases char-
acterized by dryness, such as psoriasis and atopic dermatitis.
 2013 Elsevier B.V. All rights reserved.1. Introduction membranes to modulate the release and bioavailability of modelBacterial cellulose (BC), also known as biocellulose, is an extra-
cellular polysaccharide produced by several bacteria of the genera
Gluconacetobacter, Agrobacter, Sarcina, among others, in the form of
a wet membrane (99% water) in the interface air/culture medium
[1]. Bacterial cellulose presents high purity and water absorption
capacity, as well as unique mechanical properties, good permeabil-
ity, and resistance to degradation [2–4]. Most of these properties
arise from BC peculiar tridimensional nanofibrillar network. Due
to its singular properties and biocompatibility [2,5], BC has trig-
gered considerable interest in several fields, but particularly in
the biomedical area, as for example, in wound dressing for skin
burns [2,5] and in artificial blood vessels for microsurgery [6].
Moreover, the peculiar nanofibrillar structure of BC should
represent a suitable macromolecular support for inclusion of drugs
and therefore for the development of specific controlled release
systems. Previous studies documented the ability of BCdrugs for percutaneous administration [7,8], and hence, they were
proposed as supports for topical or transdermal drug delivery.
Therapeutic feasibility is dependent on the skin compatibility of
these supports; however, little information is available concerning
the skin compatibility and irritation potential of BC-based bioma-
terials. Cytotoxicity studies have been conducted with human cells
[9–11]. However, reports regarding in vivo biocompatibility are
rather scarce and mainly used mice surgeries [9,11,12]. Clinical
tests have been conducted with commercial biocellulose films
mainly for wound healing effect [13] which account for their der-
mal compatibility, but this parameter has not been objectively
characterized. Only one study described the absence of skin irrita-
tion when a biocellulose mask was applied for 24 h to the arm of
human volunteers [14]. To our knowledge, the present study is
the first report of human skin irritation evaluation of BC mem-
branes under occlusion. Patch testing after single application is a
widely used procedure to evaluate acute irritant reactions [15].
In this methodology, occlusion is achieved by means of an alumi-
num chamber in order to exaggerate exposition conditions. A
24 h patch test with a follow-up reading at 24 h after patch
removal is recommended as optimal procedure [16]. The evalua-
tion of irritant reactions can be accomplished with objective and, Eur. J.
2 I.F. Almeida et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2014) xxx–xxxsubjective methods. Visual scoring, although subjective, can be a
sensitive, reliable, and reproducible method [17]. Several bioengi-
neering techniques have been developed to provide objective and
quantitative data. Transepidermal water loss (TEWL) is considered
to be the first choice to evaluate slight skin reactions as it detects
disrupted epidermal barrier that results in a higher loss of TEWL
[18]. However, water barrier function and water evaporation from
the skin are neither felt nor seen, and therefore, findings based on
TEWL measurements are indirect and not automatically clinically
relevant [19]. In this work, the evaluation of irritant reactions
was carried out with a combined approach in order to cover the
different features of skin irritation. The aim of the present study
was to evaluate the skin irritant potential of BC membranes (with
and without glycerin) and characterize their skin moisturizing
effect.2. Materials and reagents
Glucose (96% purity), glycerin (99.5%), and Na2HPO4 were
purchased from Sigma–Aldrich. Yeast extract and bacteriological
peptone were purchased from Himedia, and citric acid (99.6%
purity) was obtained from Acros Organics. Glycerin solution
(99%) was purchased from Fagron, and sodium lauryl sulfate
(SLS, 99% purity) was obtained from Fluka. All other chemicals
were of analytical grade. Patch test was performed with aluminum
chambers (12 mm, Finn Chambers, Epitest) fixed with adhesive
tape (Scanpore, Norgeplaster).
2.1. BC production and purification
BC membranes were produced using Gluconacetobacter sacchari
[3]. The pre-inocula were prepared at 30 C during 48 h, in static
conditions, in Hestrin and Shramm (HS) liquid medium (20 g/L glu-
cose, 5 g/L peptone, 5 g/L yeast extract, 2.7 g/L Na2HPO4, 1.15 g/L
citric acid, agar, 15 g/L, pH 5), before inoculation (10% v/v) of
50 mL into 500 mL liquid production medium in Erlenmeyer flasks.
The flasks were kept at 30 C, in static conditions, for 96 h. After the
incubation period, the BC membranes were withdrawn from the
culture medium and treated with 0.5 M NaOH at 90 C for
30 min. This procedure was repeated three times in order to elim-
inate attached cells [20]. Then, the membranes were washed with
distilled water to remove components of the culture medium and
other residues until its whitening and reaching pH 7.0.
2.2. Preparation of BC and BC-glycerin (BC-Gly) membranes
BC discs (7 cm diameter) were prepared from 8 mm thick wet
membranes (167 mg dry weight). BC discs for testing were placed
in a Petri dish and dried at 40 C in a ventilated oven for 16 h; BC
membranes were previously drained down to 40% water content
by hand-pressing between two acrylic plates at room temperature.
BC-Gly membranes were prepared by soaking BC discs in 8 mL of
an aqueous buffered solution (pH 7.4) of 1% glycerin, during 48 h
at room temperature to assure complete absorption of glycerin.
After the total absorption of the solution, BC-Gly membranes were
placed over a Petri dish and dried as described above. The dried BC
(about 5% residual water) and BC-Gly membranes (about 5% residual
water and 32% glycerin) were kept in a desiccator until their use.
2.3. Characterization of BC and BC-glycerin (BC-Gly) membranes
morphology and mechanical performance
Scanning Electron Microscopy (SEM) of the surface and cross-
section of dried BC and BC-Gly membranes were performed using
a Hitachi SU-70 instrument operating at 4 kV. BC and BC-GlyPlease cite this article in press as: I.F. Almeida et al., Bacterial cellulose memb
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covered with evaporated carbon. For cross-section analysis, the
samples were previously broken with liquid nitrogen to expose
appropriated cross-section regions.
Tensile assays were performed on an Instron machine 5966 Ser-
ies, using a load cell of 500 N, operating at a deformation rate of
10 mm/min, under ambient conditions. At least 5 specimens were
tested for each composite. Tensile strength, tensile modulus, and
elongation at break were calculated using the Bluehill 3 Material
Testing software.
2.4. In vivo evaluation
Fifteen healthy individuals (12 female and 3 male) with a mean
age of 31.1 ± 9.9 years participated in this study, and written in-
formed consent was obtained from all volunteers. BC and BC-Gly
samples were tested. SLS (2% w/v) was the positive control, and
an empty chamber was used as negative control. An aqueous glyc-
erin solution was also tested. Test sites were randomized between
volunteers. The products were applied in the inner forearm (Fig. 1),
and the patches were removed after 24 h. The visual assessment of
the degree of irritation was made at 2 and 24 h after patch removal
and graded by an experienced dermatologist according to a 5-level
reference scale [21]. In the same time intervals, TEWL measure-
ments were performed with a Tewameter (TM 210, Cour-
age + Khazaka, Germany), and erythema was evaluated with a
Colorimeter (CR-400, Minolta, Japan). Skin moisturizing effect was
assessed with a Corneometer (CM 825, MPA 9, Courage-Khazaka,
Germany). All measurements were made in a draught-free room,
with controlled temperature (18.6–22.5 C) and relative humidity
(41.4–60%). The volunteers were asked not to apply any topical
products in the forearms 24 h before the beginning and throughout
the test period. Additionally, solar exposure and use of occlusive
clothes on the test area were forbidden. The study was carried
out in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involving hu-
mans and was approved by the ethics committee of the Faculty of
Pharmacy of the University of Porto.
2.5. Statistical analysis
Statistical evaluation of erythema, moisturizing effect, and
TEWL data (variation from basal values) was performed using AN-
OVA. Post hoc comparisons with negative control were performed
with Dunnett test. Statistical analysis was conducted with IBM
SPSS Statistics 21 (a = 0.05).3. Results and discussion
3.1. Membrane characterization
BC and BC-Gly membranes were considered in this study, since
glycerin is normally used as a plasticizer, to increase malleability,
as well as the swelling (by promoting water holding and retention)
of topical delivery systems [7,8]. Fig. 2 displays the visual aspect of
BC and BC-Gly dried membranes. BC-Gly membranes are slightly
more translucent than pure BC membranes and also quite homoge-
neous which clearly indicates a good dispersion of glycerin inside
the BC nano- and microfibrills network surely due to the establish-
ment of strong interactions between the two OH rich structures.
The surface and cross-section morphology of dried BC and
BC-Gly membranes was assessed by SEM (Fig. 3). The surface
micrographs of both BC and BC-Gly membranes showed the
characteristic tridimensional nanofibrillar network of BC matrices;
however, in BC-Gly, it is less compacted, certainly because of the
presence of glycerin that limited the extent of collapse of theranes as drug delivery systems: An in vivo skin compatibility study, Eur. J.
Fig. 1. Sequential steps of the patch test using Finn Chambers.
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between the cellulose nanofibers, reducing the intermolecular
attraction forces and therefore increasing the distance between
them. This behavior is particularly noticeable on the cross-section
images where the typical lamellar morphology is much more
expanded for BC-Gly rather than for BC.
In terms of mechanical properties, as intended, the addition of
glycerin to the BC membranes increased considerably their mallea-
bility as observed by the increment in the elongation at break and
by the corresponding decrease in the Young modulus of BC-Gly
when compared to BC (Table 1). This feature is quite significant
in terms of the clinical application of BC membranes since benda-
ble type materials are easier to fix and to use.
3.2. In vivo tests
Significant differences were observed for TEWL and erythema
for the positive control (SLS), and the irritation scores were differ-
ent from zero for all volunteers, for both measuring times. These
findings confirm the validity of the procedure undertaken. Regard-
ing BC membranes, no significant differences were observed for
TEWL measurements in comparison with negative control, 2 and
24 h after patch removal (Fig. 4), which is an indicator of an ab-
sence of barrier disruption. Similar results were found for ery-
thema (Fig. 5). Clinical scores were zero at both times for all
volunteers, with the exception of five volunteers that exhibited
weak reactions (scores 1 or 2). From these, two volunteers also pre-
sented weak reactions to the negative control (Table 2). None of
the individuals reported subjective irritation symptoms like sting-
ing or itching. Taken together, these results confirm the good skin
tolerance of both BC and BC-Gly membranes.
BC-Gly membranes provided a skin moisturizing effect, statisti-
cally higher than the negative control (p = 0.044) 2 h after patch re-
moval which was not observed for BC alone (Fig. 6). OcclusionFig. 2. Visual aspect of dried BC and BC-Gly membranes.
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however, the moisturizing ability observed was similar to that
exhibited by an aqueous solution of glycerin, a well-known mois-
turizer widely used in skin care preparations. Besides, occlusion
of the untreated site did not induce a relevant increase in skin
hydration (Fig. 6). Skin hydration decreased 24 h after patch re-
moval. The persistence of the moisturizing effect could be evalu-
ated after long-term application. The role of glycerin in skin
moisturization is well documented [22] and has been traditionally
attributed to its highly hygroscopic nature associated with the
presence of three hydroxyl groups. Glycerin present in BC-Gly
membranes diffused into the stratum corneum and retained water
in this skin layer. Among other biological actions, anti-irritant
properties and recovery of the skin barrier functions have also been
reported for this polyol [23]. For these reasons, formulations con-
taining this moisturizer have been tested in the treatment for der-
matosis with damaged barrier such as atopic dermatitis and in the
treatment of dry skin conditions such as winter and senile xerosis
[24–26]. As a consequence, it may be reasonably postulated the
application of BG-Gly membranes in the therapy of skin lesions
where moisturization ameliorates the clinical symptoms. This ef-
fect can also be complement with the therapeutic action of a drug
loaded on BC membrane such as an anti-inflammatory or an anti-
pruritic compound. Besides therapeutic application, BC mem-
branes have been studied for cosmetic use [14]. It was reported
that a facial BC mask applied for 5 min promoted an increase in
skin moisture. This effect was attributed to the water content of
the mask that augmented the water uptake by the skin. This mech-
anism cannot explain the effect observed in this study since the BC
membranes used were previously dried and their water content
was low (610%). In the above mentioned study, the majority of
the volunteers rated the cellulose mask comfortable to use [14].
The mask also adhered well to the skin. Consumer/patient compli-
ance is an important issue regarding clinical efficacy. It has been
reported that failure to comply with prescribed topical treatment
can be as high as 60%, especially in chronic dermatosis such as pso-
riasis [27]. Poor cosmetic acceptability has been recognized as one
of the reasons for non-adherence [27]. The results obtained in the
study with a cellulose mask [14] cannot be fully transposed to the
system studied in this work, since different preparation methods
were used. However, it provides good indicators regarding cos-
metic acceptability of BC-based preparations.
The ability of BC membranes to modulate the release of drugs
can reduce the number of applications which offers a more simple
and convenient therapeutic regimen especially considering chronic
dermatosis. Membrane flexibility given by glycerin is highly
valuable considering the need for adaptation to skin irregularranes as drug delivery systems: An in vivo skin compatibility study, Eur. J.
Table 1
Young modulus, tensile strength and elongation at break of BC and BC-Gly







BC 19132.32 ± 1286.15 2.26 ± 0.73 271.93 ± 62.06
BC-Gly 9412.06 ± 747.70 6.17 ± 0.73 360.30 ± 51.00
Fig. 5. Erythema measurements 2 h and 24 h after patch removal. (A) BC
membrane; (B) BC-Gly membrane; (C) Glycerin solution, and (D) Negative control.
Outliers are represented as circles.
Fig. 3. Surface (left) and cross-section (right) SEM images of oven dried BC and BC-Gly membranes.
Fig. 4. TEWL measurements 2 h and 24 h after patch removal. (A) BC membrane;
(B) BC-Gly membrane; (C) Glycerin solution, and (D) Negative control. Outliers are
represented as circles.
4 I.F. Almeida et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2014) xxx–xxxareas. The membranes can also be cut (or is situ conformable) into
the desired shape and dimensions to fit the target area.Please cite this article in press as: I.F. Almeida et al., Bacterial cellulose memb
Pharm. Biopharm. (2014), http://dx.doi.org/10.1016/j.ejpb.2013.08.008Another critical issue regarding the use of topical semisolid for-
mulations is the loss of material due to contact with garments or
surfaces [8]. Regarding dose accuracy, for semisolids, the amount
of drug used and application area are patient-dependent and there-
fore are not accurate and vary widely with the patient perception.
In a topical delivery system based on BC, the dose can be precisely
defined by the membrane area applied to the skin, and the charac-
teristics of such a system prevent any loss of drug after application.
Advantages over traditional transdermal patches can also be
pointed out, such as a lower number of layers which render lower
production costs.ranes as drug delivery systems: An in vivo skin compatibility study, Eur. J.
Table 2
Irritation scores obtained in the patch test.
Score/Time Untreated BC BC-Gly SLS Glycerin solution
2 h 24 h 2 h 24 h 2 h 24 h 2 h 24 h 2 h 24 h
0 13 15 11 14 11 14 0 0 14 15
1 2 0 3 1 2 1 1 2 1 0
2 0 0 1 0 2 0 4 2 0 0
3 0 0 0 0 0 0 0 2 0 0
4 0 0 0 0 0 0 3 6 0 0
5 0 0 0 0 0 0 7 3 0 0
Fig. 6. Capacitance measurements 2 h and 24 h after patch removal. (A) BC
membrane; (B) BC-Gly membrane; (C) Glycerin solution, and (D) Negative control.
Outliers are represented as circles.
I.F. Almeida et al. / European Journal of Pharmaceutics and Biopharmaceutics xxx (2014) xxx–xxx 54. Conclusions
The good skin tolerance found after 24 h patch test reinforces
the putative interest of BC membranes as supports for topical or
transdermal drug delivery. It should be mentioned, however, that
use tests are needed to confirm skin compatibility under normal
use conditions. The inclusion of glycerin besides increasing mallea-
bility results in a skin moisturizing effect, which could be clinically
relevant for the treatment for skin diseases characterized by dry-
ness such as psoriasis and atopic dermatitis.
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